hydrocortisone acetate 10 MG/ML / pramoxine hydrochloride 10 MG/ML Rectal Cream

What the CMS Formulary Data Shows for hydrocortisone acetate 10 MG/ML / pramoxine hydrochloride 10 MG/ML Rectal Cream

Per the CMS 2026 Part D formulary file, hydrocortisone acetate 10 MG/ML / pramoxine hydrochloride 10 MG/ML Rectal Cream (RxNorm concept RXCUI 1235049, generic name hydrocortisone acetate) appears on 13 distinct formulary files spanning 251 Medicare Part D plan offerings - 5% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 4, with a cross-plan average of Tier 2.7.

Real-world access to hydrocortisone acetate 10 MG/ML / pramoxine hydrochloride 10 MG/ML Rectal Cream depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 430 Part D beneficiaries filled hydrocortisone acetate 10 MG/ML / pramoxine hydrochloride 10 MG/ML Rectal Cream in 2023, with total plan-and-beneficiary spending of $527,716 and an average per-beneficiary annual cost of $1,227.25. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry hydrocortisone acetate 10 MG/ML / pramoxine hydrochloride 10 MG/ML Rectal Cream today.